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Sacral neuromodulation (SNM) is used for the treatment of
patients with overactive bladder when first-line therapies, such as
antimuscarinics, do not provide sufficient efficacy [1]. Recently,
advances have been made in identifying optimal stimulation
parameters [2–5], as well as neural pathways [6] and neurotrans-
mitter systems that contribute to the neuromodulation’s inhibitory
effects on urinary micturition reflex [7]. However, neuromodula-
tion of bladder function has usually been studied acutely (minutes)
in anesthetized rats or cats and cannot address questions regarding
continuous therapy in patients.
A few studies have used rodent models to evaluate chronic
effects of neuromodulation [8–10]. These studies have shown pos-
itive effects, such as reducing the frequency of micturition in rat
models of cystitis induced by intravesical administration of hydro-
chloric acid [8]. However, amount of stimulation varied signifi-
cantly between studies as did the system (exteriorized wires
versus an implanted device). There is a distinct need to use and
study commercialized devices and clinically relevant parameters
to further increase understanding of SNM’s effects and to
optimize therapy.
The goal of this study was to develop and test a large animal
model to evaluate effects of SNM in conscious sheep. Bilateral
SNM was applied at a frequency of 10 Hz, which has been shown
to be optimal for inhibition of bladder contractions [2,3], using
clinically relevant current intensity and pulse-width.
2 Methods
For device implantation, female sheep (60–80 kg, n¼ 4) was
anesthetized with intravenous propofol (6 mg/kg in combination
with 1–3% isoflurane). Two stimulating leads (Model 3889, Med-
tronic, Inc.) were bilaterally implanted in the sacral foramina (S2
or S3). Leads were connected to two InterStim II devices (Model
3058, Medtronic, Inc.). Motor thresholds (VTh) were tested intra-
operatively to confirm lead targeting. After surgery, sheep was
allowed to recover for 2 weeks before urodynamics. Urodynamics
with 10 voiding trials were performed weekly in conscious, sling-
restricted sheep. A double-lumen catheter (12F) was inserted
through the urethra into the bladder. The inner lumen of the cathe-
ter was connected to a pump for infusing the bladder with saline,
and attached to a pressure sensor at the tip to monitor bladder ac-
tivity (Biopac Systems, Goleta, CA). The outer lumen was
attached to a 3–5 ml balloon filled with saline to secure the blad-
der catheter. In each urodynamic trial, saline was infused into the
bladder via the syringe pump (30 ml/min) until voiding occurred.
Voiding consisted of a large amplitude bladder contraction
(>30 mmHg) with void behaviors (arched back and bent legs).
Saline infusion was terminated and the bladder was emptied. The
infused volume of saline was recorded as bladder capacity. The
stimulation voltage of motor threshold (VTh) was obtained by turn-
ing on each InterStim II device independently and increasing volt-
age until visual confirmation of motor twitching in the appropriate
muscle target (perianal area or leg). Maximum tolerable stimula-
tion voltage (VMax) was the highest voltage at which sheep
remained calm. For SNM testing, stimulation (10 Hz, 0.21 ms
pulse-width) was applied at VTh or VMax intensity during the
fourth to fifth bladder void (two voids) or fourth to tenth void
(seven voids).
All data are expressed as mean 6 SEM. The capacity of the first
void was excluded from analysis and data were normalized to the
mean capacity of the second and third baseline values. Results
were analyzed with repeated measure repeated measures analysis
of variance (ANOVA) (GraphPad Software, Inc., San Diego, CA).
A value of p< 0.05 was considered statistically significant.
3 Results
Figure 1 shows a typical example of urodynamics, summarized
in Fig. 2. In this sheep, the bladder capacities were 103 ml and
260 ml prior to and with SNM at VMax, 10 Hz, respectively.
There was no significant change in bladder capacity if electrical
stimulation was not applied (Fig. 2). Capacity during stimulation
at VTh and VMax for two trials changed to 76 6 1% (p¼ 0.20) and
204 6 60% of controls (versus 96 6 11%, without stimulation,
p¼ 0.18), respectively. There was no functional delay between
application of the stimulus and effect on the bladder, i.e., the blad-
der capacity of the next void was 140 6 42 ml when the stimula-
tion at VMax was applied while the baseline capacity was
87 6 23 ml. The capacity returned back close to the baseline value
(84 6 13 ml) after stimulation was terminated. Finally, repeated
measure ANOVA analysis demonstrates a significant increase in
bladder capacity to VMax stimulation for seven trials (p¼ 0.02).
The mean bladder capacity increased to 245 6 40% of control
(from 42 6 8 ml to 100 6 19 ml, versus 94 6 16%, without
stimulation).
4 Interpretation
These data are an early phase demonstration that acute sacral
neuromodulation can cause quantitative changes in urodynamic
Fig. 1 Representative recording prior to ((a), no stim) and with
(b) bilateral sacral neuromodulation at VMax (VMax stim, 10 Hz,
pulse-width 5 0.21 ms). Time scale is shown above the graph.
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measures in unanesthetized, conscious sheep. The urodynamic
changes parallel clinical therapeutic responses to SNM measured
in patients using urodynamics and patient diaries [11]. SNM has
been tested previously using urodynamics in rats [10,12] and prior
data from anesthetized rodents and cats have been used to support
neuromodulation therapy for bladder control [2,3]. Here, we pro-
vide an initial description of responses to SNM in conscious sheep
using urodynamic quantification.
This novel model will greatly facilitate testing and development
of future neuromodulation therapies for bladder control. Perhaps,
most valuable will be the ability to test therapies over long dura-
tions (weeks to years) in studies of therapy maintenance that bet-
ter match clinical use.
In this study, electrical stimulation increased bladder capacity
in conscious sheep. The increase was induced by relatively high
intensity SNM (above VTh). We have reported the bladder inhibi-
tory effects of SNM in the rat are intensity-dependent. Attenuation
is stronger with increase in the stimulation current [2,4]. Future
work will need to better understand the relationships between
stimulation parameters and bladder capacity changes over time as
well as the long-term changes that may occur during continuous
stimulation in this testing model. Future studies will also focus on
the stimulation induced changes in motor and maximal tolerated
amplitudes we observed here.
5 Conclusion
Sacral nerve stimulation using permanently implanted SNM
increases bladder capacity in conscious, unanesthetized sheep.
This model appears to be feasible for testing of implantable
neuromodulation devices as well as SNM parameters to test dif-
ferent therapeutic responses to confirm and extend clinical thera-
peutic concepts.
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Fig. 2 Effects of sacral neuromodulation on bladder capacity
measured using urodynamics. Filled symbols denote measures
during stimulation. Open symbols are measures without stimu-
lation. Sacral neuromodulation during voids 4–5 applied at VTh
(10 Hz, 0.21 ms pulse-width) caused no change in capacity while
stimulation at VMax caused transient but nonsignificant
increases in mean capacity. On a subsequent test, neuromodu-
lation during voids 4–10 induced significant increases in
capacity over baseline. Responses are represented as a
percentage of baseline control capacities (mean of voids 2–3).
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